← All trials
NCT05022212
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Mar 31, 2023
- First posted
- Aug 26, 2021
- Last posted
- Aug 26, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Osel, Inc.Lead sponsor
- University of Kwa-Zulu NatalCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoCollaborator
- Harvard UniversityCollaborator
- Aurum InstituteCollaborator
- Health Systems TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.